此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Anisodine Hydrobromide for Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Treatment: A Phase Ib Dose-Escalation Study

Safety and Tolerability of Anisodine Hydrobromide in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Treatment: A Phase Ib, Open-Label, Nonrandomized, 3+3 Dose-Escalation Study

This study is an investigator-initiated Phase Ib clinical trial employing a prospective, single-center, open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of anisodine hydrobromide in patients with acute vertebrobasilar artery occlusion undergoing endovascular treatment and to determine the recommended dose for subsequent clinical studies.

研究概览

详细说明

This study is an investigator-initiated, prospective, single-center Phase Ib clinical trial designed to evaluate the safety and tolerability of anisodine hydrobromide administered to patients with acute vertebrobasilar artery occlusion undergoing endovascular treatment. The trial adopts an open-label, non-randomized, 3+3 dose-escalation design to identify the maximum tolerated dose (MTD) and determine the recommended Phase II dose (RP2D).

研究类型

介入性

注册 (估计的)

24

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age 18 to 80 years.
  2. Diagnosis of acute ischemic stroke.
  3. Time from stroke onset to first dose of study medication ≤24 hours.
  4. Imaging-confirmed acute vertebrobasilar artery occlusion (VBAO), including basilar artery occlusion, bilateral intracranial vertebral artery occlusion, or vertebrobasilar tandem occlusion.
  5. Eligible for and planned to undergo emergency endovascular treatment.
  6. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6.
  7. Posterior circulation Alberta Stroke Program Early CT Score (pcASPECTS) ≥6.
  8. No definite extensive irreversible infarction on posterior circulation imaging assessment.
  9. Pre-stroke modified Rankin Scale (mRS) score of 0-1.
  10. Written informed consent obtained from the participant or their legally authorized representative.

Exclusion Criteria:

  1. Evidence of intracranial hemorrhagic disease on head CT, including hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.
  2. History of congenital or acquired bleeding disorders, coagulation factor deficiencies, or thrombocytopenic disorders.
  3. Vascular anatomical conditions expected to prevent successful completion of endovascular treatment.
  4. Known severe allergy to iodinated contrast media.
  5. Pregnancy or breastfeeding, or planning to become pregnant during the study period or within 90 days after enrollment.
  6. Known allergy to anisodine hydrobromide or a history of severe intolerance following previous administration.
  7. Concomitant clinical conditions that may be exacerbated by anticholinergic drugs, including but not limited to angle-closure glaucoma, urinary retention, prostatic hypertrophy with difficulty urinating, or paralytic ileus.
  8. Severe cardiac arrhythmias (e.g., tachyarrhythmias requiring electrical cardioversion or recurrent syncope) or hemodynamic instability (e.g., requiring vasopressors or persistent hypotension).
  9. Severe psychiatric disorders, dementia, or impaired consciousness that would prevent the participant from providing informed consent or completing follow-up.
  10. Malignancy or other severe systemic diseases with an expected survival of less than 90 days.
  11. Participation in another interventional clinical study within 30 days before enrollment, or current participation in another interventional clinical study.
  12. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:单组作业
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Anisodine Hydrobromide 1.0 mg

Participants receive anisodine hydrobromide 1.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

实验性的:Anisodine Hydrobromide 1.5 mg

Participants receive anisodine hydrobromide 1.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

实验性的:Anisodine Hydrobromide 2.0 mg

Participants receive anisodine hydrobromide 2.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

实验性的:Anisodine Hydrobromide 2.5 mg

Participants receive anisodine hydrobromide 2.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Occurrence of Predefined Safety Events Within 8 Days
大体时间:Within 8 days after the first administration

The primary safety outcome is the occurrence of predefined safety events within 8 consecutive days after the first administration of the study drug. Predefined safety events include: (1) symptomatic intracranial hemorrhage (sICH), defined as intracranial hemorrhage confirmed by neuroimaging in conjunction with neurological deterioration, operationalized as an increase of at least 4 points in the NIHSS score; (2) death from any cause; and (3) any other serious adverse event (SAE), excluding the foregoing events, that is adjudicated by the Data Monitoring Committee (DMC) to be definitely, probably, or possibly related to the study drug.

Within 8 days after the first administration

次要结果测量

结果测量
措施说明
大体时间
Early Neurological Deterioration
大体时间:Within 24 hours after treatment initiation

Early neurological deterioration is defined as worsening in neurological status within 24 hours after treatment initiation. Neurological status is assessed using the National Institutes of Health Stroke Scale (NIHSS), a validated clinical instrument for assessing stroke severity. The NIHSS total score ranges from 0 to 42, with higher scores indicating greater neurological impairment.

Within 24 hours after treatment initiation
Infarct Volume
大体时间:Day 8

Infarct volume measured on non-contrast cranial computed tomography (CT) at Day 8, expressed in milliliters (mL).

Day 8
Functional Outcome (Modified Rankin Scale)
大体时间:Day 90

Functional outcome assessed using the modified Rankin Scale (mRS) at Day 90. The mRS score ranges from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability. The distribution of mRS scores will be reported.

Day 90
Incidence of Symptomatic Intracranial Hemorrhage
大体时间:Within 8 days after the first administration

Incidence of symptomatic intracranial hemorrhage (sICH) confirmed by neuroimaging and accompanied by neurological deterioration, defined as an increase of at least 4 points in the NIHSS score, within 8 days after the first administration of the study drug.

Within 8 days after the first administration
Incidence of Any Intracranial Hemorrhage
大体时间:Within 8 days after the first administration

Incidence of any intracranial hemorrhage detected by neuroimaging within 8 days after the first administration of the study drug, regardless of whether neurological deterioration is present.

Within 8 days after the first administration
Incidence of Study Drug-Related Adverse Events
大体时间:Within 90 days after the first administration

Incidence of adverse events (AEs) occurring within 90 days after the first administration of the study drug that are considered definitely, probably, or possibly related to anisodine hydrobromide.

Within 90 days after the first administration
Incidence of Study Drug-Related Serious Adverse Events
大体时间:Within 90 days after the first administration

Incidence of serious adverse events (SAEs) occurring within 90 days after the first administration of the study drug that are considered definitely, probably, or possibly related to anisodine hydrobromide.

Within 90 days after the first administration
All-Cause Mortality
大体时间:Within 90 days after the first administration

All-cause mortality occurring within 90 days after the first administration of the study drug.

Within 90 days after the first administration

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Yu Feng, MD, PhD、The Affiliated Hospital of Xuzhou Medical University
  • 研究主任:Yanbo Cheng, MD, PhD、The Affiliated Hospital of Xuzhou Medical University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月20日

初级完成 (估计的)

2027年1月20日

研究完成 (估计的)

2027年1月20日

研究注册日期

首次提交

2026年11月15日

首先提交符合 QC 标准的

2026年11月15日

首次发布 (实际的)

2026年11月19日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月15日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅